Assessment of the safety, tolerance, and immunogenicity of EG-HPV (human papillomavirus vaccine) in healthy male adult volunteers: A double-blinded, randomized, adjuvant vehicle-controlled trial

Trial Profile

Assessment of the safety, tolerance, and immunogenicity of EG-HPV (human papillomavirus vaccine) in healthy male adult volunteers: A double-blinded, randomized, adjuvant vehicle-controlled trial

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Human papillomavirus vaccine (Primary) ; Aluminium-hydroxide/CIA-05; CIA-05
  • Indications Cervical cancer; Human papillomavirus infections; Penile cancer
  • Focus Adverse reactions
  • Sponsors EyeGene
  • Most Recent Events

    • 25 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top